<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="ctdna-cd20-baff-odronextamab-luminari">
    <meta name="study:title" content="PF999 - Longitudinal targeted ctDNA analysis to assess CD20 and BAFF mutations in patients (pts) with relapsed/refractory (R/R) FL or DLBCL progressing on Odronextamab treatment in the ELM-2 study">
    <meta name="study:fileName" content="Abstracts/CTDNA-CD20-BAFF-ODRONEXTAMAB-LUMINARI-PF999.html">
    <meta name="study:cancerTypes" content="FL,DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Odronextamab,Bispecific antibodies,Anti-CD20 antibody">

    <title>PF999: ctDNA CD20/BAFF Mutations in R/R FL/DLBCL (Luminari) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF999 - ctDNA Analysis of CD20/BAFF Mutations in R/R FL/DLBCL on Odronextamab (ELM-2)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=121 Pts with ctDNA)</h4>
                    <p>R/R FL/DLBCL Pts on Odronextamab (ELM-2). Aim: Identify mutations (CD20, BAFF, etc.) assoc. with PD via ctDNA analysis.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods</h4>
                    <p>Longitudinal plasma ctDNA (CAPP-Seq) & matched tumor biopsies (WGS). Targeted 8-gene immune resistance panel.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Findings (Mutations at PD/MRD+)</h4>
                    <p>On-Tx CD20 mutations in 16.3% (7/43), BAFF in 32.6% (14/43). Many not detected at BL. CD20 p.S129F & BAFF p.E6K common.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Tx-emergent CD20/BAFF mutations may contribute to PD. ctDNA useful for detecting resistance beyond MRD.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF999 - Longitudinal targeted ctDNA analysis to assess CD20 and BAFF mutations in patients (pts) with relapsed/refractory (R/R) FL or DLBCL progressing on Odronextamab treatment in the ELM-2 study</h1>
            <p class="abstract-sub-header">David Tucker, Jon E. Arnason, Stefano Luminari, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF999 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Odronextamab (CD20×CD3 bispecific Ab) showed compelling efficacy (ORR FL 80%, DLBCL 52%) and manageable safety in R/R FL/DLBCL (ELM-2 study, NCT03888105).</li>
                        <li>All patients (pts) had prior anti-CD20 antibody Tx and were CAR T-cell therapy naïve.</li>
                        <li>Undetectable Minimal Residual Disease (MRD) at Week 12 (W12) with odronextamab was associated with PFS benefit.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To identify mutations associated with progressive disease (PD) in adults with R/R Follicular Lymphoma (FL Grade 1-3a) or Diffuse Large B-Cell Lymphoma (DLBCL) treated with odronextamab in the ELM-2 study, using longitudinal ctDNA analysis.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study: Phase 2 ELM-2 (NCT03888105).</li>
                        <li>Patients: R/R FL or DLBCL receiving IV odronextamab until PD or unacceptable toxicity.</li>
                        <li>Sample Collection: Plasma for ctDNA at baseline (BL), on Tx (W12 ± 7 days), and at PET-CT (Q12W for CR pts). Matched BL tumor biopsies (≤180 days pre-Tx) if available.</li>
                        <li>Sequencing:
                            <ul class="list-circle list-inside ml-4">
                                <li>ctDNA: CAPP-Seq with a targeted immune resistance panel (8 B-cell target genes: CD20, CD19, CD22, CD58, CD79B, BAFF, BAFFR, BCMA).</li>
                                <li>Tumor Biopsies: Whole Genome Sequencing (WGS).</li>
                            </ul>
                        </li>
                        <li>Data Cutoff: Aug 15, 2024.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">ELM-2: ctDNA Mutation Analysis in R/R FL/DLBCL</h3>
                        <div class="schema-enrollment">
                            <strong>Pts from ELM-2 Study (N=121 with ctDNA samples)</strong>
                            <span>R/R FL or DLBCL on Odronextamab</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Sample Collection & Sequencing</strong>
                                <span>Plasma ctDNA: Baseline, On-Tx (W12), at PET-CT (CR pts) -> CAPP-Seq (8-gene panel)</span>
                                <span>Matched Tumor Biopsy (BL, if available) -> WGS</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Detection of somatic mutations in target genes (CD20, BAFF, etc.)</span>
                           <span>Correlation of mutations with PD or MRD+ status</span>
                           <span>Comparison of ctDNA vs. tumor biopsy mutation detection</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: ctDNA Sequencing & Mutation Analysis</h2>
                    <p class="text-sm mb-2">155 ctDNA samples from 121 pts sequenced. 101 pts had PD (FL n=20; DLBCL n=39) or were MRD+ at W12 without PD (FL n=15; DLBCL n=27). Control: 20 MRD- pts (BL ctDNA sequenced).</p>
                    <p class="text-sm font-semibold mt-3 mb-1">Baseline (BL) ctDNA Mutations (N=107 pts):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Somatic mutations detected in all 8 genes tested.</li>
                        <li>CD20: 7.5% (FL n=6; DLBCL n=2).</li>
                        <li>CD19: 11.2%.</li>
                        <li>CD22: 14.0%.</li>
                        <li>CD58: 8.4%.</li>
                        <li>CD79B: 15.9%.</li>
                        <li>BAFF: 6.5%.</li>
                        <li>BAFFR: 8.4%.</li>
                        <li>BCMA: 3.7%.</li>
                        <li>BL CD20 mutations did not appear to predict response to odronextamab.</li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">Comparison of BL ctDNA vs. Tumor Biopsy (N=49 pts with biopsies):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Of 57 mutations in BL ctDNA, only 15 (26.3%) were also in tumor biopsies.</li>
                        <li>No BL tumor mutations detected in CD22, BAFF, BAFFR, or BCMA.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">On-Treatment (W12) Mutations in Pts with PD and/or MRD+ (N=43):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>CD20 Mutations:</strong> 7 pts (16.3%; FL n=3, DLBCL n=4).
                            <ul class="list-circle list-inside ml-4">
                                <li>5/7 had p.S129F (predicted to impair CD20 expression).</li>
                                <li>Not detected at BL in 4/7 (3 had no BL sample).</li>
                                <li>PD in 4/7 with detectable CD20 mutation around progression.</li>
                            </ul>
                        </li>
                        <li><strong>BAFF Mutations:</strong> 14 pts (32.6%; FL n=5, DLBCL n=9).
                             <ul class="list-circle list-inside ml-4">
                                <li>13/14 had p.E6K (predicted non-deleterious, potentially activating).</li>
                                <li>Not detected at BL in 9/14 (5 had no BL sample).</li>
                                <li>PD in 7/14 with detectable BAFF mutation around progression.</li>
                            </ul>
                        </li>
                        <li>One FL pt in CR for ≥1 year had both CD20 p.S129F and BAFF p.E6K mutations at BL.</li>
                    </ul>
                     <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure: CD20 and BAFF Mutations</h3>
                        <img src="Assets/Tucker_Mechanismsofresistance_EHA2025_Fig_Final.png" alt="Figure A: CD20 mutations. Figure B: BAFF mutations. Detected at baseline and on odronextamab treatment." class="mx-auto rounded-lg shadow-md" style="max-width: 100%; height: auto;" onerror="this.onerror=null;this.src='https://placehold.co/600x400/EBF4FA/1E3A8A?text=Figure+Not+Available';">
                        <p class="text-xs text-center mt-2 italic">Figure: Circulating tumor DNA mutations detected at baseline and on odronextamab treatment for A. CD20 and B. BAFF. aa, amino acid.</p>
                    </div>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This analysis suggests that disease progression in pts with R/R FL or DLBCL treated with odronextamab could be partially attributable to treatment-emergent CD20 and BAFF mutations.</li>
                <li>Minimally invasive ctDNA analysis (CAPP-Seq) showed utility beyond MRD determination, detecting more mutations than WGS from tumor biopsies, possibly due to greater sequencing depth.</li>
                <li>Emergence of specific CD20 (e.g., p.S129F) and BAFF (e.g., p.E6K) mutations on treatment was observed in a subset of patients with PD or MRD positivity.</li>
                <li>Ongoing analyses of ctDNA samples at earlier timepoints will help determine whether CD20/BAFF variant detection before PD can predict clinical outcomes.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>Ab, Antibody; AE, Adverse Event; BAFF, B-cell Activating Factor; BAFFR, BAFF Receptor; BCMA, B-Cell Maturation Antigen; BL, Baseline; CAPP-Seq, Cancer Personalized Profiling by Deep Sequencing; CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CR, Complete Response; ctDNA, Circulating Tumor DNA; DLBCL, Diffuse Large B-Cell Lymphoma; ELM-2, Study Name; FL, Follicular Lymphoma; IV, Intravenous; MRD, Minimal Residual Disease; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; PD, Progressive Disease; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; Pts, Patients; Q12W, Every 12 Weeks; R/R, Relapsed/Refractory; Tx, Treatment; W, Week; WGS, Whole Genome Sequencing.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Tucker D, Arnason JE, Luminari S, et al. Longitudinal targeted ctDNA analysis to assess CD20 and BAFF mutations in patients (pts) with relapsed/refractory (R/R) FL or DLBCL progressing on Odronextamab treatment in the ELM-2 study. Abstract #PF999 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF999 | Abstract Release: 05/14/25 | Presentation: 06/13/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    </body>
</html>
